Sarah Schellhorn Mougalian, MD

Articles by Sarah Schellhorn Mougalian, MD

Adverse Prognostic Features in Chronic Lymphocytic Leukemia

BySarah Schellhorn Mougalian, MD,Susan O’Brien, MD

July 15th 2011

Our ability to stratify patients with CLL into high-risk and low-risk categories has advanced dramatically over the past two decades. However, which test or tests are most reliable remains to be seen.

Latest Updated Articles

Adverse Prognostic Features in Chronic Lymphocytic Leukemia
July 15th 2011

Trending on CancerNetwork

FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy

Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer

FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer

FDA Accepts sNDA for Taletrectinib in ROS1-Positive NSCLC

TIP127 TroFuse-012: A Phase 3, Randomized Study of Adjuvant Sacituzumab Tirumotecan Plus Pembrolizumab Vs Treatment of Physician’s Choice in Participants With Triple-Negative Breast Cancer who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response at Surgery